Weitz & Luxenberg provides information on Actos Bladder Cancer
Recently, Actos bladder cancer has been discussed in the news. In June 2011, The FDA issued a warning that Actos may be linked to bladder cancer. The risk seems to be considerably higher for those that take the drug at “higher cumulative doses and for longer periods of time, usually 24 months or more.” (The Wall Street Journal)
Actos Bladder Cancer
The European Market
Although Actos continues to remain on the shelves of drug stores in the United States, France and Germany “have temporarily suspended the drug,” (The Wall Street Journal) out of concern for its citizens. This “puts the future of Takeda Pharmaceuticals, the manufacturer, in a rather precarious position,” (The Wall Street Journal) not just in France and Germany, but all across the European continent.
In order to address this concerning issue Takeda has agreed to sponsor a study that will scrutinize the Actos bladder cancer issue. However, “the FDA stresses that there is no definitive proof that Actos causes bladder cancer and that patients who are currently taking it should continue to do so, unless otherwise advised by their health care provider.” (Web MD)
Actos Bladder Cancer
What does Actos do?
Actos is a drug for patients living with type 2 diabetes, although it can also work to balance good and bad levels of cholesterol as well. When used in conjunction with proper diet and frequent exercise, Actos can effectively reduce the level of glucose (sugar) in your blood stream.
Weitz & Luxenberg is currently investigating cases involving Actos bladder cancer. If you would like to tell us about your experience with Actos, please fill out the form on this page.
The Wall Street Journal:
Actos and Death Actos potentially related to bladder cancer and death: learn more.
Are there bladder-cancer related deaths associated with Actos? Weitz & Luxenberg is currently investigating. Visit us for more information.
Actos Suspended in Europe JAMA affirms Actos bladder cancer risks: File an Actos Lawsuit today
File an Actos lawsuit today. Weitz & Luxenberg informs clients that Journal of American Medicine affirms risk of bladder cancer.
Gadolinium The gadolinium contrast dye used in MRIs may cause nephrogenic systemic fibrosis (NSF)
Did you develop Nephrogenic Systemic Fibrosis (NSF) from Gadolinium dye? Weitz & Luxenberg can help.